SLN
Silence TherapeuticsยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
SLN Profile
Silence Therapeutics Plc
A leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases
Biological Technology
11/18/1994
09/08/2020
NASDAQ Stock Exchange
116
12-31
Depository Receipts (Ordinary Shares)
72 Hammersmith Road, London, W14 8TH United Kingdom
--
Silence Therapeutics Plc was incorporated on 18 November 1994 as a public limited company under the laws of England and Wales. The company is a biotechnology company focused on the discovery and development of new molecules, including short interfering ribonucleic acid (siRNA), to inhibit the expression of specific target genes that are thought to play a role in the pathological processes of diseases with significant unmet medical needs.
